COVID-19 relapse associated with SARS-CoV-2 evasion from CD4+ T-cell recognition in an agammaglobulinemia patient

无丙种球蛋白血症患者中,SARS-CoV-2逃避CD4+ T细胞识别导致COVID-19复发

阅读:2
作者:Ryo Morita ,Ritsuko Kubota-Koketsu ,Xiuyuan Lu ,Tadahiro Sasaki ,Emi E Nakayama ,Yu-Chen Liu ,Daisuke Okuzaki ,Daisuke Motooka ,James Badger Wing ,Yasunori Fujikawa ,Yuji Ichida ,Kiyoko Amo ,Tetsushi Goto ,Junichi Hara ,Michinori Shirano ,Sho Yamasaki ,Tatsuo Shioda

Abstract

A 25-year-old patient with a primary immunodeficiency lacking immunoglobulin production experienced a relapse after a 239-day period of persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Viral genetic sequencing demonstrated that SARS-CoV-2 had evolved during the infection period, with at least five mutations associated with host cellular immune recognition. Among them, the T32I mutation in ORF3a was found to evade recognition by CD4+ T cells. The virus found after relapse showed an increased proliferative capacity in vitro. SARS-CoV-2 may have evolved to evade recognition by CD4+ T cells and increased in its proliferative capacity during the persistent infection, likely leading to relapse. These mutations may further affect viral clearance in hosts with similar types of human leukocyte antigens. The early elimination of SARS-CoV-2 in immunocompromised patients is therefore important not only to improve the condition of patients but also to prevent the emergence of mutants that threaten public health.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。